On October 30, JD HEALTH recorded an Intraday Rise of 3.28% in Regular Trading, with the stock trading at HK$37.3 and turnover of HK$51.96 million.
The latest market update points to a broader rebound in Hong Kong-listed healthcare and large-cap technology names, with JD HEALTH moving in tandem with that sector strength. In the same Internet & Direct Marketing Retail group, MEITUAN-W rose 4.12%, PA GOODDOCTOR rose 2.84%, JD-SW rose 2.49%, ALI HEALTH rose 2.36%, and BABA-W rose 1.25%.
Fundamentally, the company previously reported interim revenue of RMB40.9 billion, up 15.9%, while Non-IFRS operating profit rose 40.3% to RMB3.5 billion, lifting operating margin to 8.5%. Its September monthly share report also showed no material change in share capital, indicating a stable capital structure. These factors help explain why the stock has participated in the sector’s recovery.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments